Cagrilintide clinical trials
Every study registered on ClinicalTrials.gov that lists Cagrilintide as an intervention, as of the data edition — what is being tested, in whom, by whom, and how far it has got.
- Registered studies
- 44
- Active or recruiting
- 18
- Completed
- 24
- With posted results
- 1
- Planned or actual enrollment
- 26,724participants, summed
| Phase | Studies | Breakdown |
|---|---|---|
| Phase 1 | 17 | 10 completed, 7 active or recruiting, 0 stopped, 0 other |
| Phase 2 | 5 | 4 completed, 0 active or recruiting, 1 stopped, 0 other |
| Phase 3 | 22 | 10 completed, 11 active or recruiting, 1 stopped, 0 other |
Conditions studied
- Obesity26
- Overweight13
- Diabetes Mellitus, Type 27
- Type 2 Diabetes6
- Type 2 Diabetes Mellitus2
- Obesity or Overweight2
- Hepatic Impairment1
- Healthy Volunteers1
- Diabetic Peripheral Neuropathy1
- Cardiovascular Disease1
- Obese1
- Obesity & Overweight1
Lead sponsors
- Novo Nordisk A/S44
The registry, study by study
Registration is not evidence of benefit; many registered studies never publish. Status and dates are as reported by sponsors to ClinicalTrials.gov.
| Study | Phase | Status | Start | n | Sponsor |
|---|---|---|---|---|---|
| NCT07817251Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Phase 3 | Recruiting | Sep 2026 | 210 | Novo Nordisk A/S |
| NCT07745504A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Phase 3 | Recruiting | Aug 2026 | 285 | Novo Nordisk A/S |
| NCT07282613A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | Phase 3 | Recruiting | Aug 2026 | 80 | Novo Nordisk A/S |
| NCT07607587Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events | Phase 1 | Recruiting | May 2026 | 114 | Novo Nordisk A/S |
| NCT07564414A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Phase 3 | Recruiting | May 2026 | 2,500 | Novo Nordisk A/S |
| NCT07597018A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity | Phase 1 | Recruiting | May 2026 | 234 | Novo Nordisk A/S |
| NCT07557953A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity | Phase 1 | Recruiting | Apr 2026 | 120 | Novo Nordisk A/S |
| NCT07527195Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) | Phase 1 | Recruiting | Apr 2026 | 100 | Novo Nordisk A/S |
| NCT07411560A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese | Phase 1 | Recruiting | Feb 2026 | 100 | Novo Nordisk A/S |
| NCT07253285A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | Phase 3 | Recruiting | Jan 2026 | 460 | Novo Nordisk A/S |
| NCT07220759Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | Phase 3 | Active, not recruiting | Nov 2025 | 330 | Novo Nordisk A/S |
| NCT07220642Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | Phase 3 | Active, not recruiting | Nov 2025 | 300 | Novo Nordisk A/S |
| NCT07184086A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | Phase 1 | Active, not recruiting | Sep 2025 | 80 | Novo Nordisk A/S |
| NCT07010432The Role of the Amylin Analogue Cagrilintide in Bone Metabolism | Phase 1 | Recruiting | Jun 2025 | 144 | Novo Nordisk A/S |
| NCT07011667A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | Phase 3 | Active, not recruiting | Jun 2025 | 609 | Novo Nordisk A/S |
| NCT06780449A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity | Phase 3 | Active, not recruiting | Feb 2025 | 400 | Novo Nordisk A/S |
| NCT05669755REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | Phase 3 | Active, not recruiting | Mar 2023 | 7,101 | Novo Nordisk A/S |
| NCT05567796A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | Phase 3 | Active, not recruiting | Nov 2022 | 3,400 | Novo Nordisk A/S |
| NCT07357740A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes | Phase 2 | Withdrawn | Aug 2026 | 0 | Novo Nordisk A/S |
| NCT07357766A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight | Phase 3 | Withdrawn | Jun 2026 | 0 | Novo Nordisk A/S |
| NCT07605052A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight | Phase 1 | Completed | May 2026 | 50 | Novo Nordisk A/S |
| NCT06797869A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | Phase 2 | Completed | Jan 2025 | 142 | Novo Nordisk A/S |
| NCT06719011A Study on How NNC0174-1213 Works in People With Overweight or Obesity. | Phase 1 | Completed | Dec 2024 | 178 | Novo Nordisk A/S |
| NCT06716307A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity | Phase 1 | Completed | Dec 2024 | 18 | Novo Nordisk A/S |
| NCT06534411A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | Phase 3 | Completed | Nov 2024 | 1,023 | Novo Nordisk A/S |
| NCT06388187A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight | Phase 3 | Completed | Jun 2024 | 300 | Novo Nordisk A/S |
| NCT06409130Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease | Phase 2 | Completed | May 2024 | 270 | Novo Nordisk A/S |
| NCT06403761Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes | Phase 1 | Completed | May 2024 | 158 | Novo Nordisk A/S |
| NCT06131372A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | Phase 2 | Completed | Apr 2024 | 626 | Novo Nordisk A/S |
| NCT06323161A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin | Phase 3 | Completed | Mar 2024 | 274 | Novo Nordisk A/S |
| NCT06323174A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | Phase 3 | Completed | Mar 2024 | 189 | Novo Nordisk A/S |
| NCT06289504A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight | Phase 1 | Completed | Feb 2024 | 34 | Novo Nordisk A/S |
| NCT06207877A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight | Phase 1 | Completed | Feb 2024 | 62 | Novo Nordisk A/S |
| NCT06267092A Study of How CagriSema Works on Appetite in People With Excess Body Weight | Phase 1 | Completed | Feb 2024 | 164 | Novo Nordisk A/S |
| NCT06221969A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Phase 3 | Completed | Jan 2024 | 1,024 | Novo Nordisk A/S |
| NCT06131437A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | Phase 3 | Completed | Nov 2023 | 809 | Novo Nordisk A/S |
| NCT06065540A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Phase 3 | Completed | Sep 2023 | 2,734 | Novo Nordisk A/S |
| NCT05996848A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight | Phase 3 | Completed | Aug 2023 | 300 | Novo Nordisk A/S |
| NCT05804162A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants | Phase 1 | Completed | Apr 2023 | 107 | Novo Nordisk A/S |
| NCT05564104A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body | Phase 1 | Completed | Apr 2023 | 32 | Novo Nordisk A/S |
| NCT05813925A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight | Phase 3 | Completed | Apr 2023 | 331 | Novo Nordisk A/S |
| NCT05394519A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight | Phase 3 | Completed | Feb 2023 | 1,200 | Novo Nordisk A/S |
| NCT04982575Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesResults posted | Phase 2 | Completed | Aug 2021 | 92 | Novo Nordisk A/S |
| NCT04940078A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity | Phase 1 | Completed | Jul 2021 | 40 | Novo Nordisk A/S |
Run this search on ClinicalTrials.gov → Query term: cagrilintide OR CagriSema